BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial | Request PDF
Motixafortide (BL-8040) | Overview | BioLineRx
Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer | Clinical Research Trial Listing ( Stage IV Pancreatic Cancer AJCC v6 and v7 | Metastatic Pancreatic Cancer | Recurrent
BioLineRx begins Phase IIa COMBAT trial of BL-8040 and Keytruda combination to treat pancreatic cancer - Clinical Trials Arena
BioLineRx's Motixafortide (BL-8040) Receives EC's ODD to Treat Pancreatic Cancer in Europe
BL-8040 Combo Shows Good Disease Control in Pancreatic Cancer
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial | Request PDF
BioLineRx Reports Results of BL-8040 in Combination with Keytruda (pembrolizumab) in P-IIb Trial for Patients with Metastatic Pancreatic Cancer
BioLineRx set to begin investigator-initiated Phase I/II trial of leukaemia drug - Clinical Trials Arena
BiolineRx: COMBAT Engagement (NASDAQ:BLRX) | Seeking Alpha
Motixafortide (BL-8040) | Overview | BioLineRx
The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression | Leukemia
Motixafortide | C97H144FN33O19S2 - PubChem
EX-2 3 exhibit_2.htm BL-8040 PRESENTATION Exhibit
BiolineRx Has Huge Upside In 2018 (NASDAQ:BLRX) | Seeking Alpha
Clinical trials of CXCR4 inhibitors in acute myeloid leukemia | Download Table
Overview of currently active clinical trials on ECM-targeted therapy. | Download Table
BioLineRx: Expands Cancer Pipeline Significantly By Acquiring Novel Drug Candidate Ready For Human Trials (NASDAQ:BLRX) | Seeking Alpha
